Bioresorbable Scaffolds: a New Paradigm in Percutaneous Coronary Intervention

Overview

Journal BMC Cardiovasc Disord

Publisher Biomed Central

Specialty Cardiology & Vascular Diseases

Date 2016 Feb 13

PMID 26868826

Citations 19

Authors

Erhan Tenekecioglu

Vasim Farooq

Christos V Bourantas

Rafael Cavalcante Silva

Yoshinobu Onuma

Mustafa Yilmaz

Patrick W Serruys

Affiliations

Soon will be listed here.

Abstract

Numerous advances and innovative therapies have been introduced in interventional cardiology over the recent years, since the first introduction of balloon angioplasty, but bioresorbable scaffold is certainly one of the most exciting and attracting one. Despite the fact that the metallic drug-eluting stents have significantly diminished the re-stenosis ratio, they have considerable limitations including the hypersensitivity reaction to the polymer that can cause local inflammation, the risk of neo-atherosclerotic lesion formation which can lead to late stent failure as well as the fact that they may preclude surgical revascularization and distort vessel physiology. Bioresorbable scaffolds overcome these limitations as they have the ability to dissolve after providing temporary scaffolding which safeguards vessel patency. In this article we review the recent developments in the field and provide an overview of the devices and the evidence that support their efficacy in the treatment of CAD. Currently 3 devices are CE marked and in clinical use. Additional 24 companies are developing these kind of coronary devices. Most frequently used material is PLLA followed by magnesium.

Citing Articles

Innovations in Vascular Repair from Mechanical Intervention to Regenerative Therapies.

Park H, Kim C, Kong D, Heo S, Park H Tissue Eng Regen Med. 2025; .

PMID: 39921820 DOI: 10.1007/s13770-024-00700-x.

Stem cells and bio scaffolds for the treatment of cardiovascular diseases: new insights.

Razavi Z, Farokhi S, Mahmoudvand G, Karimi-Rouzbahani A, Farasati-Far B, Tahmasebi-Ghorabi S Front Cell Dev Biol. 2024; 12:1472103.

PMID: 39726717 PMC: 11669526. DOI: 10.3389/fcell.2024.1472103.

Safety and efficacy of Mg-Dy membrane with poly-L-lactic acid coating for guided bone regeneration.

On S, An H, Lee S, Choi Y, Woo J, Hong S Sci Rep. 2024; 14(1):25522.

PMID: 39462023 PMC: 11513034. DOI: 10.1038/s41598-024-77211-1.

Advances in Fabrication Technologies for the Development of Next-Generation Cardiovascular Stents.

Das A, Mehrotra S, Kumar A J Funct Biomater. 2023; 14(11).

PMID: 37998113 PMC: 10672426. DOI: 10.3390/jfb14110544.

Advances in the development of biodegradable coronary stents: A translational perspective.

Zong J, He Q, Liu Y, Qiu M, Wu J, Hu B Mater Today Bio. 2022; 16:100368.

PMID: 35937578 PMC: 9352968. DOI: 10.1016/j.mtbio.2022.100368.

References

Stone G, Ellis S, Cox D, Hermiller J, OShaughnessy C, Mann J . A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004; 350(3):221-31. DOI: 10.1056/NEJMoa032441. View

Lafont A, Durand E . A.R.T.: concept of a bioresorbable stent without drug elution. EuroIntervention. 2011; 5 Suppl F:F83-7. DOI: 10.4244/EIJV5IFA14. View

Onuma Y, Serruys P, Ormiston J, Regar E, Webster M, Thuesen L . Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention. 2010; 6(4):447-53. DOI: 10.4244/EIJ30V6I4A76. View

Gruntzig A, SENNING A, SIEGENTHALER W . Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med. 1979; 301(2):61-8. DOI: 10.1056/NEJM197907123010201. View

Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C . Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007; 369(9562):667-78. DOI: 10.1016/S0140-6736(07)60314-6. View

Serruys P, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G . A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994; 331(8):489-95. DOI: 10.1056/NEJM199408253310801. View

Nishio S, Kosuga K, Igaki K, Okada M, Kyo E, Tsuji T . Long-Term (>10 Years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents. Circulation. 2012; 125(19):2343-53. DOI: 10.1161/CIRCULATIONAHA.110.000901. View

Barlis P, Tanigawa J, Di Mario C . Coronary bioabsorbable magnesium stent: 15-month intravascular ultrasound and optical coherence tomography findings. Eur Heart J. 2007; 28(19):2319. DOI: 10.1093/eurheartj/ehm119. View

Haude M, Erbel R, Erne P, Verheye S, Degen H, Bose D . Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet. 2013; 381(9869):836-44. DOI: 10.1016/S0140-6736(12)61765-6. View

10.

Ormiston J, Serruys P, Regar E, Dudek D, Thuesen L, Webster M . A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008; 371(9616):899-907. DOI: 10.1016/S0140-6736(08)60415-8. View

11.

Gruntzig A . Transluminal dilatation of coronary-artery stenosis. Lancet. 1978; 1(8058):263. DOI: 10.1016/s0140-6736(78)90500-7. View

12.

Serruys P, Strauss B, Beatt K, Bertrand M, Puel J, Rickards A . Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med. 1991; 324(1):13-7. DOI: 10.1056/NEJM199101033240103. View

13.

Garg S, Serruys P, Onuma Y, Dorange C, Veldhof S, Miquel-Hebert K . 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System.... JACC Cardiovasc Interv. 2010; 2(12):1190-8. DOI: 10.1016/j.jcin.2009.10.002. View

14.

Brugaletta S, Radu M, Garcia-Garcia H, Heo J, Farooq V, Girasis C . Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque?. Atherosclerosis. 2012; 221(1):106-12. DOI: 10.1016/j.atherosclerosis.2011.12.008. View

15.

Waksman R, Pakala R, Kuchulakanti P, Baffour R, Hellinga D, Seabron R . Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries. Catheter Cardiovasc Interv. 2006; 68(4):607-17. DOI: 10.1002/ccd.20727. View

16.

Windecker S, Kolh P, Alfonso F, Collet J, Cremer J, Falk V . 2014 ESC/EACTS guidelines on myocardial revascularization. EuroIntervention. 2014; 10(9):1024-94. DOI: 10.4244/EIJY14M09_01. View

17.

Jabara R, Pendyala L, Geva S, Chen J, Chronos N, Robinson K . Novel fully bioabsorbable salicylate-based sirolimus-eluting stent. EuroIntervention. 2011; 5 Suppl F:F58-64. DOI: 10.4244/EIJV5IFA10. View

18.

Garg S, Serruys P . Biodegradable stents and non-biodegradable stents. Minerva Cardioangiol. 2009; 57(5):537-65. View

19.

Gordon P, Gibson C, Cohen D, Carrozza J, Kuntz R, Baim D . Mechanisms of restenosis and redilation within coronary stents--quantitative angiographic assessment. J Am Coll Cardiol. 1993; 21(5):1166-74. DOI: 10.1016/0735-1097(93)90241-r. View

20.

Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Juni P, Vaina S . Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol. 2008; 52(14):1134-40. DOI: 10.1016/j.jacc.2008.07.006. View